Single HPV vaccine dose offers long-term protection against cervical cancer

A single dose of the human papillomavirus (HPV) vaccine is as effective as multiple doses for preventing preinvasive cervical disease that can later develop into cervical cancer, according to a new study. In the UK, girls and boys aged 12 to 13 years will be routinely offered two doses of HPV vaccination with the second dose normally offered 6 to 12 months after the first. The study was published in CANCER, a journal of the American Cancer Society, and included 133,082 females aged 9 to 26 years who were unvaccinated  (66,541) or who received one or more HPV vaccine (66,541) doses between January 2006 and June 2015.